Neutralizing potency of COVID-19 vaccines against the SARS-CoV-2 Omicron (B.1.1.529) variant

Giuseppe Lippi¹, Camilla Mattiuzzi², Brandon M Henry^{3

4}

Affiliations

¹ School of Medicine, Section of Clinical Biochemistry, University of Verona, Verona, Italy.
² Service of Clinical Governance, Provincial Agency for Social and Sanitary Services, Trento, Italy.
³ Clinical Laboratory, Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
⁴ Disease Intervention & Prevention and Population Health Programs, Texas Biomedical Research Institute, San Antonio, Texas, USA.

Giuseppe Lippi et al. J Med Virol. 2022 May.

. 2022 May;94(5):1799-1802.

doi: 10.1002/jmv.27575. Epub 2022 Jan 12.

Giuseppe Lippi¹, Camilla Mattiuzzi², Brandon M Henry^{3

4}

¹ School of Medicine, Section of Clinical Biochemistry, University of Verona, Verona, Italy.
² Service of Clinical Governance, Provincial Agency for Social and Sanitary Services, Trento, Italy.
³ Clinical Laboratory, Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
⁴ Disease Intervention & Prevention and Population Health Programs, Texas Biomedical Research Institute, San Antonio, Texas, USA.

No abstract available

Conflict of interest statement

The author declares that there are no conflict of interests.

1. Wang L, Cheng G. Sequence analysis of the emerging SARS‐CoV‐2 variant Omicron in South Africa. J Med Virol. Published online December 12, 2021. 10.1002/jmv.27516 - DOI - PubMed
1. Saxena SK, Kumar S, Ansari S, et al. Characterization of the novel SARS‐CoV‐2 Omicron (B.1.1.529) variant of concern and its global perspective. J Med Virol. Published online December 14, 2021. 10.1002/jmv.27524 - DOI - PubMed
1. Dejnirattisai W. Reduced neutralisation of SARS‐CoV‐2 Omicron B.1.1.529 variant by post‐immunisation serum. Lancet. Published online December 20, 2021. 10.1016/S0140-6736(21)02844-0 - DOI - PMC - PubMed
1. Ai J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than other SARS‐CoV‐2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect. Published online December 22, 2021. 10.1080/22221751.2021.2022440 - DOI - PMC - PubMed
1. Garcia‐Beltran WF St, Denis KJ, Hoelzemer A, et al. mRNA‐based COVID‐19 vaccine boosters induce neutralizing immunity against SARS‐CoV‐2 Omicron variant. medRxiv. 2021. 10.1101/2021.12.14.21267755 - DOI - PMC - PubMed